title: [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
abstract: OBJECTIVE
  To analyze the potential improvement of (18)F-fluorodeoxyglucose (FDG) PET/CT using additional delayed images of the liver in operated colorectal cancer.
  
  
  METHODS
  The study prospectively included 71 patients (22 women, 49 men) with mean age of 65 ± 11 years with clinical, analytic or radiological suspicion of current disease. A whole body PET/CT scan was performed at 60 min. (standard images) and after 2 hr (delayed images) post-injection of 4.07 MBq/Kg of (18)F-FDG. Visual and quantitative SUV analysis of PET/CT findings was done. All findings were confirmed by histopathology and/or at least 6 months follow-up.
  
  
  RESULTS
  Thirty-seven out of 71 patients were diagnosed of liver metastases (79 metastases). In 38/71 cases there was extra-hepatic disease in the form of local recurrence (10), abdominopelvic (3) or mediastinal (3) lymph nodes, bone (1) or lung metastases (16) and carcinomatosis (10). Sensitivity and specificity in the diagnosis of liver metastases in a patient-by-patient basis in standard (81% and 91%) and in delayed images (95% y 97%) was calculated. The number of lesions detected in delayed images was significantly higher (66/79) than in standard images (57/79). Sensitivity and specificity for PET/CT in the diagnosis of extra-hepatic disease was 84% and 70%, contributing to the detection of synchronous tumors in 5 patients.
  
  
  CONCLUSIONS
  PET/CT may be useful in the diagnosis of extra-hepatic disease in suspected recurrence of colorectal cancer. Delayed images on PET/CT may increase the sensitivity to identify liver metastases.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínic, Barcelona, España. dfuster@clinic.ub.es
authors.forename: D
authors.initials: D
authors.lastname: Fuster
authors.forename: S
authors.initials: S
authors.lastname: Lafuente
authors.forename: X
authors.initials: X
authors.lastname: Setoain
authors.forename: I
authors.initials: I
authors.lastname: Navales
authors.forename: A
authors.initials: A
authors.lastname: Perissinotti
authors.forename: J
authors.initials: J
authors.lastname: Pavia
authors.forename: P
authors.initials: P
authors.lastname: Paredes
authors.forename: F
authors.initials: F
authors.lastname: Lomeña
authors.forename: F
authors.initials: F
authors.lastname: Pons
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000628:therapy; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D010386:Pelvic Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18